Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia.
Lopez-Millan B, Costales P, Gutiérrez-Agüera F, Díaz de la Guardia R, Roca-Ho H, Vinyoles M, Rubio-Gayarre A, Safi R, Castaño J, Romecín PA, Ramírez-Orellana M, Anguita E, Jeremias I, Zamora L, Rodríguez-Manzaneque JC, Bueno C, Morís F, Menendez P. Lopez-Millan B, et al. Among authors: jeremias i. Cancers (Basel). 2022 Mar 21;14(6):1593. doi: 10.3390/cancers14061593. Cancers (Basel). 2022. PMID: 35326743 Free PMC article.
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR, Velasco Hernandez T, Diaz de la Guardia R, Castaño J, Anguita E, Vives S, Nomdedeu J, Lapillone H, Bras AE, van der Velden VHJ, Junca J, Marin P, Bataller A, Esteve J, Vick B, Jeremias I, Lopez A, Sorigue M, Bueno C, Menendez P. Baroni ML, et al. Among authors: jeremias i. J Immunother Cancer. 2020 Jun;8(1):e000845. doi: 10.1136/jitc-2020-000845. J Immunother Cancer. 2020. PMID: 32527933 Free PMC article.
Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing.
Sánchez-Martínez D, Gutiérrez-Agüera F, Romecin P, Vinyoles M, Palomo M, Tirado N, Zanetti SR, Juan M, Carlet M, Jeremias I, Menéndez P. Sánchez-Martínez D, et al. Among authors: jeremias i. Clin Transl Med. 2021 Feb;11(2):e280. doi: 10.1002/ctm2.280. Clin Transl Med. 2021. PMID: 33634970 Free PMC article.
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.
Zanetti SR, Velasco-Hernandez T, Gutierrez-Agüera F, Díaz VM, Romecín PA, Roca-Ho H, Sánchez-Martínez D, Tirado N, Baroni ML, Petazzi P, Torres-Ruiz R, Molina O, Bataller A, Fuster JL, Ballerini P, Juan M, Jeremias I, Bueno C, Menéndez P. Zanetti SR, et al. Among authors: jeremias i. Mol Ther. 2022 Feb 2;30(2):550-563. doi: 10.1016/j.ymthe.2021.08.033. Epub 2021 Sep 1. Mol Ther. 2022. PMID: 34478871 Free PMC article.
Requirement for LIM kinases in acute myeloid leukemia.
Jensen P, Carlet M, Schlenk RF, Weber A, Kress J, Brunner I, Słabicki M, Grill G, Weisemann S, Cheng YY, Jeremias I, Scholl C, Fröhling S. Jensen P, et al. Among authors: jeremias i. Leukemia. 2020 Dec;34(12):3173-3185. doi: 10.1038/s41375-020-0943-5. Epub 2020 Jun 26. Leukemia. 2020. PMID: 32591645 Free PMC article.
Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.
Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Thölken M, Meyer LM, Nguyen TD, Campe J, Moser LM, Hock S, Baker F, Meyer CT, Wempe F, Serve H, Ullrich E, Jeremias I, Münch C, Brandts CH. Koschade SE, et al. Among authors: jeremias i. Leukemia. 2022 Oct;36(10):2396-2407. doi: 10.1038/s41375-022-01678-y. Epub 2022 Aug 23. Leukemia. 2022. PMID: 35999260 Free PMC article.
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.
Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, André MC, Hiddemann W, Schneider S, Subklewe M, Metzeler KH, Spiekermann K, Jeremias I. Vick B, et al. Among authors: jeremias i. PLoS One. 2015 Mar 20;10(3):e0120925. doi: 10.1371/journal.pone.0120925. eCollection 2015. PLoS One. 2015. PMID: 25793878 Free PMC article.
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, Metzeler KH, Dörfel D, Salih HR, Jung G, Nößner E, Jeremias I, Hiddemann W, Leonhardt H, Spiekermann K, Subklewe M, Greif PA. Reiter K, et al. Among authors: jeremias i. Leukemia. 2018 Feb;32(2):313-322. doi: 10.1038/leu.2017.257. Epub 2017 Aug 14. Leukemia. 2018. PMID: 28895560 Free PMC article.
Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.
Garz AK, Wolf S, Grath S, Gaidzik V, Habringer S, Vick B, Rudelius M, Ziegenhain C, Herold S, Weickert MT, Smets M, Peschel C, Oostendorp RAJ, Bultmann S, Jeremias I, Thiede C, Döhner K, Keller U, Götze KS. Garz AK, et al. Among authors: jeremias i. Oncotarget. 2017 Oct 16;8(65):108738-108759. doi: 10.18632/oncotarget.21877. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312564 Free PMC article.
145 results